Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: Comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases

European Urology

Volumn 43, Issue 4, 2003, Pages 342-350

  Martínez Piñeiro, Luis ^a   Rios, Emilio ^a   Martínez Gomariz, Montserrat ^b   Pastora, Teresa ^a   De Cabo, Mónica ^a   Picazo, María L ^a   Palacios, José ^a   Perona, Rosario ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Blood; Cancer; Lymph node; Prostate; RT PCR

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SCORING SYSTEM; STANDARD; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

EID: 0037386651     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00055-1     Document Type: Article

References (28)

1. Corey E, Corey MJ. Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): Technical and clinical aspects. Int J Cancer 1998;77:655-73.
2. Laufer M, Pound CF, Carducci MA, Eisenberger M. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000;55:309-15.
3. Clobes H. Foss SD, Wæhm H, Jocham D, Bemer A. The immunohistochemical assessment of occult regional lymph node metastases in patients with T3pN0M0 prostate cancer before definitive radiotherapy. Br J Urol 2000;85:270-5.
4. Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen S, Young LL, et al. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 1995;154:474-8.
5. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997;158:326-37.
6. Olsson CA, de Vries GM, Buttyan R, Katz AE. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am 1997;24:367-78.
7. Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Dallow KC, et al. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996;47:370-5.
8. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase-polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 2000; 163:1183-8.
9. Chomozysky P, Sacchi N. Single step method of RNA isolation by guanidium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;162:156-9.
10. Israeli RS, Miller Jr WH, Su SL, Samdi DS, Powell CT, Heston WDW, et al. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 1995;153:573-7.
11. Amling CL, Blute ML, Bergstralh EJ. Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5.
12. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
14. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24: 395-406.
15. Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, McLeod DG. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. Urology 1994;43-:68-73.
16. Wood Jr DP, Banerjee M. Presence of circulating prostate cells in bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. J Clin Oncol 1997;15:3451-7.
17. Mejean A, Vona G, Nalpas B. Damotte D, Brousse N, Chretien Y, et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 2000;163:2022-9.
18. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate-specific antigen and prostate- specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998;58:1456-9.
19. Olsson CA, deVries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557-62.
20. Okegawa T, Nutahara K, Higashihara E. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. Br J Urol 1999;84:112-7.
21. Gao C, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, et al. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction, J Urol 1999;161:1070-6.
22. Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993; 53:5350-4.
23. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997;89:1498-504.
24. Lin DW, Ellis WJ, True LD, Felise DG, Lange PH, Vessella RL. Reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of prostate cancer micrometastases in pelvic lymph nodes (LN), bone marrow (BM) and peripheral blood (PB). J Urol 1999;161:908A.
25. Ferrari AC, Stone NN, Wallace W, Stock RG, Mandeli J, Unger P, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in pelvic lymph nodes (PLN) of men with localized prostate cancer: correlation with risk factors and PSA failure. J Urol 2000;163:824A.
26. Mao H, Hoshi S, Takahashi T, Kaneda T, Wang J, Suzuki K, et al. Detection of PSA mRNA from the peripheral blood and pelvic lymph nodes in patients with prostatic cancer by means of reverse transcription-polymerase chain reaction (RT-PCR). Nippon Hinyokika Gakkai Zasshi 1998;89:596-603.
27. Okegawa T, Noda H, Kato M, Miyata A, Nutahara K, Higashihara E. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 2000;44:210-8.
28. Potter SR, Mangold LA, Shue MJ, Taylor DC, Lecksell KL, Epstein JI, et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 2000;89:2577-86.